Dermatomyositis
113
26
32
47
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
23 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 39/100
9.7%
11 terminated out of 113 trials
81.0%
-5.5% vs benchmark
14%
16 trials in Phase 3/4
49%
23 of 47 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 47 completed trials
Clinical Trials (113)
Intralesional Injection of STS in Treatment of Calcinosis
Environmental Risk Factors for the Anti-synthetase Syndrome
Biomarkers of Cancer-Associated Myositis
Environmental Risk Factors for Myositis in Military Personnel
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
Adult and Juvenile Myositis
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties
Add-on Intravenous Immunoglobulins in Early Myositis
Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Rheumatology Patient Registry and Biorepository
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
RCT of Tocilizumab for Anti-MDA5+DM
MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)